Trizepatide (Mounjaro) is a dual GIP and GLP-1 receptor agonist that improves blood sugar control, enhances insulin sensitivity, and reduces appetite. Clinical studies highlight its effectiveness in supporting significant weight loss, better metabolic health, and reduced cardiovascular risk in individuals with type 2 diabetes and obesity.
Trizepatide (Mounjaro)
Original price was: $200.00.$160.00Current price is: $160.00.
Description
Concentration – 10 mg per vial
Physical Form – Lyophilized powder (sterile 3 mL vial)
Product Features
-
Freeze-dried for maximal shelf stability
-
Butyl rubber stopper allows multiple punctures while maintaining a secure seal
-
Vials are depyrogenated, ETO-sterilized, and finished with a tamper-evident aluminum flip-top
Research Highlights
Dual GIP/GLP-1 Receptor Agonist: Trizepatide activates both GIP and GLP-1 pathways, amplifying insulin secretion, reducing glucagon levels, and improving glycemic control.
Weight Reduction: Clinical studies demonstrate significant and sustained weight loss through enhanced satiety, reduced appetite, and improved energy expenditure.
Metabolic Health: Research highlights improvements in HbA1c, insulin sensitivity, lipid profiles, and cardiovascular risk markers in type 2 diabetes and obesity.
Liver & Cardiovascular Benefits: Preclinical and clinical findings suggest potential in reducing hepatic steatosis, supporting cardiovascular health, and lowering inflammation.
Emerging Applications: Ongoing investigations explore roles in metabolic syndrome, cardiovascular disease prevention, and broader weight management strategies beyond diabetes.
Reviews
There are no reviews yet.